obesitas satiety and obesity
Conditions
Interventions
Patients undergo gastroduodenoscopy/colonoscopy for a medical reason. If a
patient decides to participate in this study, 6-8 biopsies of the duodenom or
ileum will be taken if no relevant abnormalit
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 3.1.2 Inclusion criteria for first part of study (duodenal biopsies): - Step 1 (patients asked for participation): 1) Patients (male and female between 18 and 65 years) referred for upper GI endoscopy (because of functional complaints) 1)2) Based on medical history and previous examination, no objection arises for taking extra biopsies during the gastroduodenoscopy. or colonoscopy. - Step 2 (patients agreed to participate and in who biopsies will be taken) 1) Patients with no relevant endoscopic abnormalities (gastroduodenoscopy): patients without gastric or duodenal ulcers/polyps/lesions suspect for malignancy and esophageal lesions or varices.;2) Based on medical history and previous examination, no objection arises for taking extra biopsies during the colonoscopy - Step 2 (patients agreed to participate and in who biopsies will be taken) 2) Patients with no relevant endoscopic abnormalities (colonoscopy): patients without ileal and/or colonic ulcers/polyps/diverticula and lesions suspect for malignancy
Exclusion criteria
Exclusion criteria: 1) History of severe cardiovascular, gastrointestinal/ hepatic, hematological/immunologic, metabolic/nutritional disease and/or laboratory assessments which might limit participation in the study. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator. 2) Use of medication, which could interfere with normal coagulation (anticoagulants, antiplatelet drugs). 3) Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator) 4) Excessive alcohol consumption (>20 alcoholic consumptions per week)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints - Measurements in serosal samples of the gut hormones Cholecystokinin (CCK), Glucagon Like Peptide-1 (GLP-1) and Peptide YY (PYY) (in pmol/mL) from human duodenal biopsies in the Ussing chamber - Measurements in serosal samples of the gut hormones Cholecystokinin (CCK), Glucagon Like Peptide-1 (GLP-1) and Peptide YY (PYY) (in pmol/mL) from human ileal biopsies in the Ussing chamber | — |
Secondary
| Measure | Time frame |
|---|---|
| - | — |
Countries
Netherlands
Outcome results
None listed